Medicare Enrolled
Dr. Madhavi Rayapudi, MD
Infectious Disease · Cumming, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rayapudi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rayapudi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rayapudi
Dr. Madhavi Rayapudi is an infectious disease specialist in Cumming, GA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Rayapudi performed 2,465,495 Medicare services across 2,422 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rayapudi received a total of $7,369 from 32 pharmaceutical and/or device companies across 396 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in infectious disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rayapudi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in GA
$7,369 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,465,495
Medicare services
Top 1% in GA for infectious disease
2,422
Unique beneficiaries
$1
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~123,275 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daptomycin antibiotic injection | 2,365,703 | $0 | $0 |
| Injection, omadacycline, 1 mg | 34,500 | $3 | $10 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
14,022 | $0 | $5 |
| Injection, meropenem, 100 mg | 11,170 | $0 | $10 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
10,119 | $1 | $20 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
6,453 | $50 | $200 |
| Dalbavancin injection, 5 mg An injection of the antibiotic dalbavancin, administered in a 5 mg dose. |
5,600 | $12 | $30 |
| Ceftazidime injection, per 500 mg An injection of the antibiotic ceftazidime, billed for every 500 mg administered. |
3,147 | $1 | $20 |
| Ertapenem sodium injection, 500 mg An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg. |
2,983 | $11 | $110 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
2,823 | $62 | $155 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
2,378 | $23 | $100 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
1,919 | $16 | $39 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,817 | $98 | $218 |
| Vancomycin injection, 500 mg A 500 mg dose of vancomycin antibiotic is administered via injection. |
959 | $2 | $30 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
388 | $8 | $30 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
291 | $136 | $412 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
190 | $141 | $294 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
167 | $94 | $300 |
| Manual urinalysis with microscopic examination A urine test performed manually without automated equipment. The sample is examined under a microscope to check for abnormalities. |
114 | $4 | $16 |
| Infusion tube insertion with imaging guidance A radiologist inserts an infusion tube into the body while using imaging guidance to ensure proper placement and reviews the procedure. |
98 | $299 | $1,500 |
| Skin and tissue removal, 20 sq cm or less This procedure involves the surgical excision of skin and underlying tissue from an area measuring 20 square centimeters or smaller. |
94 | $93 | $239 |
| Skin substitute graft application, 25 sq cm or less Application of a skin substitute graft to a wound on the trunk, arms, or legs covering 25 square centimeters or less. |
94 | $122 | $288 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
91 | $70 | $250 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
81 | $131 | $334 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
66 | $94 | $211 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
55 | $1 | $20 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
54 | $18 | $41 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
49 | $92 | $297 |
| Chemical application to prevent wound tissue regrowth A chemical agent is applied to a wound to inhibit the regrowth of tissue. This procedure focuses on the application of the substance to manage the wound bed. |
43 | $58 | $162 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
16 | $11 | $55 |
| New patient office visit, complex (60-74 min) | 11 | $163 | $419 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.9% high complexity
98.9% medium
0.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,369
Total received (2018-2024)
Avg $1,053/year across 7 years
Top 22% in GA for infectious disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
32
Companies
396
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,075 (96.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$262 (3.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$32 (0.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,238
2023
$1,368
2022
$1,292
2021
$1,196
2020
$729
2019
$776
2018
$771
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ViiV Healthcare Company
$286
Takeda Pharmaceuticals U.S.A., Inc.
$181
Gilead Sciences, Inc.
$154
Cumberland Pharmaceuticals, Inc.
$131
Insmed, Inc.
$85
Merck Sharp & Dohme LLC
$74
La Jolla Pharmaceutical Company
$65
ABBVIE INC.
$59
Organogenesis Inc.
$52
PFIZER INC.
$42
ADMA BioManufacturing LLC
$32
Astellas Pharma US Inc
$30
MIMEDX Group, Inc.
$17
Grifols USA, LLC
$16
Paratek Pharmaceuticals, Inc.
$15
Top 3 companies account for 50.1% of 2024 payments
All-time payments by company (2018-2024) ›
ViiV Healthcare Company
$1,352
Paratek Pharmaceuticals, Inc.
$712
Gilead Sciences, Inc.
$683
Takeda Pharmaceuticals U.S.A., Inc.
$646
Insmed, Inc.
$595
Cumberland Pharmaceuticals, Inc.
$510
Merck Sharp & Dohme Corporation
$342
La Jolla Pharmaceutical Company
$336
ABBVIE INC.
$318
PFIZER INC.
$270
Merck Sharp & Dohme LLC
$210
Melinta Therapeutics, Inc.
$209
Astellas Pharma US Inc
$193
AbbVie Inc.
$192
AbbVie, Inc.
$161
Grifols USA, LLC
$115
Romark Laboratories, LC
$102
CSL Behring
$54
Organogenesis Inc.
$52
Smith & Nephew, Inc.
$47
Melinta Therapeutics, LLC
$38
ADMA BioManufacturing LLC
$32
Allergan, Inc.
$26
Philips Electronics North America Corporation
$25
Kedrion Biopharma Inc.
$23
MAYNE PHARMA INC.
$23
Dynavax Technologies Corporation
$21
ADVANCED RESPIRATORY, INC
$21
TETRAPHASE PHARMACEUTICALS, INC.
$18
MIMEDX Group, Inc.
$17
Shire North American Group Inc
$15
Ferring Pharmaceuticals Inc.
$12
Top 3 companies account for 37.3% of all-time payments
Associated products mentioned in payments ›
AVYCAZ · Alinia · Alinia Tablets 500mg 30 count bottle · Arikayce · Baxdela · CABENUVA · CAPVAXIVE · CRESEMBA · CUVITRU · Cresemba · DALVANCE · DIFICID · DOVATO · Gamunex-C · HYQVIA · Heplisav-B · Hizentra · ISENTRESS · JULUCA · Kedrab · Kimyrsa · MAVYRET · Mavyret · NOXAFIL · NUZYRA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · PANZYGA · PIFELTRO · PREVNAR - 13 · RUKOBIA · Rezzayo · Santyl · TEFLARO · TRIUMEQ · The Vest System Model 105 Home Care · VIBATIV · Vabomere · Vibativ · XERAVA · Xembify · ZERBAXA · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Infectious diseases within 10 mi
31
Per 100K population
11.9
County median income
$138,000
Nearest hospital
NORTHSIDE HOSPITAL FORSYTH
4.9 mi
4.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rayapudi is a mixed practice specialist, with above-average Medicare volume (top 1% in GA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rayapudi experienced with daptomycin antibiotic injection?
Based on Medicare claims data, Dr. Rayapudi performed 2,365,703 daptomycin antibiotic injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rayapudi receive payments from pharmaceutical companies?
Yes. Dr. Rayapudi received a total of $7,369 from 32 companies across 396 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rayapudi's costs compare to other infectious diseases in Cumming?
Dr. Rayapudi's average Medicare payment per service is $1. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rayapudi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Infectious Diseases in Cumming
Browse infectious diseases in Cumming ranked by procedure volume and transparency data.
Highest volume
Top Infectious Diseases in GA
Infectious diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Infectious Diseases in GA
Which GA infectious diseases receive the most from drug and device companies.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
By company
Paratek Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Paratek Pharmaceuticals, Inc.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology